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Abstract
Background: Tranexamic acid prevents blood clots from breaking down and reduces bleeding. However, it is
uncertain whether tranexamic acid is effective in traumatic brain injury. The CRASH-3 trial is a randomised
controlled trial that will examine the effect of tranexamic acid (versus placebo) on death and disability in 13,000
patients with traumatic brain injury. The CRASH-3 trial hypothesizes that tranexamic acid will reduce intracranial
haemorrhage, which will reduce the risk of death. Although it is possible that tranexamic acid will reduce
intracranial bleeding, there is also a potential for harm. In particular, tranexamic acid may increase the risk of
cerebral thrombosis and ischaemia. The protocol detailed here is for a mechanistic sub-study nested within the
CRASH-3 trial. This mechanistic sub-study aims to examine the effect of tranexamic acid (versus placebo) on
intracranial bleeding and cerebral ischaemia.
Methods: The CRASH-3 Intracranial Bleeding Mechanistic Sub-Study (CRASH-3 IBMS) is nested within a prospective,
double-blind, multi-centre, parallel-arm randomised trial called the CRASH-3 trial. The CRASH-3 IBMS will be
conducted in a cohort of approximately 1000 isolated traumatic brain injury patients enrolled in the CRASH-3 trial.
In the CRASH-3 IBMS, brain scans acquired before and after randomisation are examined, using validated methods,
for evidence of intracranial bleeding and cerebral ischaemia. The primary outcome is the total volume of intracranial
bleeding measured on computed tomography after randomisation, adjusting for baseline bleeding volume. Secondary
outcomes include progression of intracranial haemorrhage (from pre- to post-randomisation scans), new intracranial
haemorrhage (seen on post- but not pre-randomisation scans), intracranial haemorrhage following neurosurgery, and
new focal ischaemic lesions (seen on post-but not pre-randomisation scans). A linear regression model will examine
whether receipt of the trial treatment can predict haemorrhage volume. Bleeding volumes and new ischaemic lesions
will be compared across treatment groups using relative risks and 95% confidence intervals.
(Continued on next page)
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Discussion: The CRASH-3 IBMS will provide an insight into the mechanism of action of tranexamic acid in traumatic
brain injury, as well as information about the risks and benefits. Evidence from this trial could inform the management
of patients with traumatic brain injury.
Trial registration: The CRASH-3 trial was prospectively registered and the CRASH-3 IBMS is an addition to the original
protocol registered at the International Standard Randomised Controlled Trials registry (ISRCTN15088122) 19 July 2011,
and ClinicalTrials.gov on 25 July 2011 (NCT01402882).
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Background
Traumatic brain injury (TBI) occurrence
TBI is a leading cause of death and disability worldwide.
According to the World Health Organization, TBI will
continue to be a major cause of death and disability by
2020 [1]. At least 200 per 100,000 people are killed or
hospitalised each year after TBI [2], resulting in over 10
million deaths or hospitalisations each year [3]. TBI is
the leading cause of death and disability in people below
the age of 45 [4].
TBI patients can experience a loss in physical, behav-
ioural or emotional functioning after the injury [5]. Severe
TBI often results in motor impairment that persists for at
least 3 years after the injury [6] and cognitive impairments
are present for at least 6 months after injury [7]. Problems
with memory following TBI significantly affect an individ-
ual’s quality of life [8]. Even with rehabilitation treatments,
only 40–50% of TBI patients completely recover [9].
The increasing incidence of TBI can be explained by the
rising frequency of traffic accidents in developing countries
and rapidly motorising middle-income countries [10]. Pro-
jections of global mortality and burden of disease suggest
that road traffic accidents will be the third major cause of
death and disability by 2030, assuming a faster rate of
socio-economic development [11]. Falls in older adults are
the leading cause of TBI in high-income countries [12].
Given the global scope of this life threatening and poten-
tially disabling condition, it is important to identify the
most effective clinical care in this patient group.
Intracranial haemorrhage occurrence
Intracranial bleeding is common after TBI and the larger
the bleed the greater the risk of death and disability
[13, 14]. In patients with mild TBI (Glasgow Coma Scale
score ≥ 13), although bleeding can continue for up to
24 hours after injury, most bleeds stop progressing within
a few hours of hospital admission [15]. Intracranial haem-
orrhage progression has been observed in half of moderate
to severe head injury patients who had a median Glasgow
Coma Scale score of 8 on admission and repeat computed
tomography (CT) scans performed within 24 hours of
injury [16, 17]. Patients who were scanned earlier after
injury (≤3.5 hours vs. > 3.5 hours) were more likely to have
expanding haematomas on CT performed 24 hours after
injury (57% vs. 28%) [17]. If the initial CT scan was con-
ducted more than 3.5 hours after injury, the percentage of
patients with measurable changes in haematoma volume
24 hours after injury was reduced. In a subset of patients
who had an intermediate scan (most of which were be-
tween 6 and 9 hours of injury), the mean volume change
between the baseline and intermediate scan was 5.7 mL,
whereas the difference in mean volume between the inter-
mediate scan and the 24 hour scan was 0.03 mL [17].
Thus, the maximal change in intracranial haemorrhage
volume occurs soon after injury.
A meta-analysis of 34 studies that reported the fre-
quency of coagulopathy after TBI found that one third
of patients with TBI have laboratory evidence of abnor-
mal coagulation based on parameters such as fibrinogen,
fibrin degradation products and antithrombin levels [18].
The risk of mortality in patients with coagulopathy
after TBI is nine times higher than in TBI patients without
coagulopathy (odds ratio (OR) 9.0, 95% confidence inter-
val (CI) 7.3–11.6). The risk of unfavourable outcome as
measured by the Glasgow Outcome Scale (score of 1–3) is
more than 30 times higher in TBI patients with coagulop-
athy (OR 36.3, 95% CI 18.7–70.5) [18]. Decreased platelet
counts, prolonged prothrombin time and partial thrombo-
plastin time, and high levels of fibrinogen and D-dimer
levels are observed in patients within the first 3 hours of
TBI [19]. The highest D-dimer concentrations were found
in the most severely injured patients [20], who have a
higher risk of intracranial haemorrhage and mortality.
Effectiveness of tranexamic acid in reducing haemorrhage
Tranexamic acid reduces bleeding by inhibiting the en-
zymatic breakdown of fibrin blood clots. Plasmin binds
to fibrin via lysine-binding sites and then splits fibrin
into fibrin degradation products. Tranexamic acid is a
molecular analogue of lysine that inhibits fibrinolysis by
reducing the binding of plasmin to fibrin.
A systematic review of 104 randomised trials of tran-
examic acid in surgical patients found that it reduced
the number of patients receiving a blood transfusion by
one-third and halved the need for further surgery to
control bleeding [21].
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A large randomised trial of tranexamic acid treatment
within an hour of acute traumatic injury found that
it reduced the risk of death due to bleeding by about
one-third (relative risk (RR) 0.68, 95% CI 0.57–0.82;
P < 0.0001) [22, 23]. Treatment between 1 and 3 hours re-
duced the risk by about one-fifth (RR 0.79, 0.64–0.97;
P = 0.03). There was no apparent increase in the risk
of vascular occlusive events with tranexamic acid follow-
ing acute trauma (RR 0.69, 95% CI 0.44–1.07; P = 0.096).
Tranexamic acid as a potential treatment in TBI
Tranexamic acid is able to penetrate the blood–brain
barrier and should be able to affect intracranial haemor-
rhage [24]. If tranexamic acid is effective following TBI,
it should also be most effective when given soon after in-
jury when intracranial bleeding is on-going [15]. Further-
more, if early increased fibrinolysis exacerbates bleeding
and increases the risk of death [20], we would expect tran-
examic acid to be most effective during this period.
However, there is also the potential for harm. In par-
ticular, tranexamic acid may increase the risk of cerebral
thrombosis and ischaemia [25]. Cerebral ischaemia is an
important secondary injury mechanism after TBI that
worsens neurologic outcome and increases mortality
[26, 27]. It can be precipitated by raised intracranial
pressure, which can lead to cerebral hypo-perfusion
[28–31]. In addition, thrombotic disseminated intravascu-
lar coagulation may increase the risk of cerebral micro-
thrombi, which are often seen in the brains of TBI patients
who die within 24 hours of injury [32]. By inhibiting fibrin-
olysis, tranexamic acid might increase the risk of cerebral
ischaemia and thrombosis in TBI patients.
A systematic review identified two completed rando-
mised trials of tranexamic acid in TBI patients [33]. The
first randomised trial (n = 249) examined the effect of
tranexamic acid in patients with extra-cranial bleeding
but who also had TBI [34]. The second randomised trial
(n = 229) examined the effect of tranexamic acid in pa-
tients with polytrauma and TBI or isolated TBI [35]. Both
trials used information from pre- and post-randomisation
CT scans to estimate the extent of bleeding and ischaemia.
Both trials recruited patients who were within 8 hours of
injury, yet they were not large enough to determine the
balance of risks and benefits from tranexamic acid and
whether this varies by time to treatment.
When the two randomised trials were combined in a
meta-analysis, there was a statistically significant reduc-
tion in intracranial haemorrhage (RR 0.75, 95% CI 0.58–
0.98; P = 0.03) and mortality (RR 0.63, 95% CI 0.40–0.99;
P = 0.05) with tranexamic acid. In one trial, focal ischae-
mic lesions occurred in 5% of tranexamic acid-treated
patients and 9% of placebo-treated patients (RR 0.51,
95% CI 0.20–1.32; P = 1.17) [34]. In the second trial,
there were three strokes in the placebo group compared
with none in the tranexamic acid group [35]. However,
because the CIs for intracranial haemorrhage, death and
ischaemic lesion outcomes are so wide, the quality of
this evidence is low. Furthermore, the patients in the tri-
als had extra-cranial bleeding in addition to intra-cranial
bleeding. Because tranexamic acid reduces mortality in
extra-cranial bleeding (CRASH-2), the mortality reduc-
tion seen in this trial could be from the extra-cranial
injury rather than any effect on the brain injury. The
effect of tranexamic acid on intracranial haemorrhage
and thrombotic adverse effects, including stroke, remains
uncertain.
There are three ongoing randomised trials of tranex-
amic acid versus placebo in patients with isolated TBI
(NCT02645552, NCT01990768, NCT01402882). These
will evaluate the effect of tranexamic acid on death, dis-
ability, vascular occlusive events and other adverse events
in TBI. The ongoing trials will inform whether tranexamic
acid can be given to those with TBI. To date, the CRASH-
3 trial, with a planned sample size of 13,000 patients, will
be the largest randomised trial into the effect of tranex-
amic acid in TBI [36]. The results from the three ongoing
trials should provide clinicians with information about
whether tranexamic acid is effective in reducing death and
disability without increasing thrombotic events. The trials
will also provide information about whether its effect var-
ies by time to treatment.
However, these trials will not provide information
about the mechanism by which tranexamic acid might
exert its effects in TBI. If tranexamic acid reduces mor-
tality by reducing intracranial haemorrhage, we would
expect there to be less blood on head CT scans of tran-
examic acid-treated patients, particularly those treated
soon after injury [25]. If tranexamic acid increases the
risk of cerebral ischaemia, we would expect to see more
ischaemic lesions in tranexamic acid-treated patients,
particularly in those treated after a more prolonged period
following injury [37]. The CRASH-3 Intracranial Bleeding
Mechanistic Sub-Study (CRASH-3 IBMS) will examine
the effect of tranexamic acid on intracranial haemorrhage
and cerebral ischaemia in a cohort of patients enrolled in
the CRASH-3 trial. This paper outlines the protocol for
the CRASH-3 IBMS and is in line with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines. The SPIRIT checklist and
figure have been included as Additional file 1 and Fig. 1,
respectively.
Aim
The CRASH-3 IBMS aims to examine the mechanism
by which tranexamic acid exerts its effects in patients
with isolated TBI. Specifically, we will assess the effect of
tranexamic acid on intracranial bleeding and cerebral
ischaemia.
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Trial design
The CRASH-3 IBMS is a mechanistic randomised con-
trolled trial nested within a larger prospective, double-
blind, multi-centre, parallel-arm, randomised, placebo
controlled trial. The CRASH-3 IBMS is nested in a co-
hort of CRASH-3 trial participants (NCT01402882)
(Fig. 2). The aims and methods of the CRASH-3 trial are
presented in detail elsewhere [36].
Methods
Participating sub-study sites, eligibility and interventions
Participating hospitals
Hospitals participating in the CRASH-3 IBMS have been
selected based on the number of patients enrolled into
the CRASH-3 trial and the willingness of the Principal
Investigator at site to take part. Four of the highest
recruiting CRASH-3 trial hospital sites in the United
Kingdom have been selected to take part (Royal London
Hospital, London; Queen Elizabeth Hospital, Birmingham;
University Hospital, Coventry; Salford Royal Hospital, Sal-
ford). Other hospitals participating in the CRASH-3 trial
will be included to meet the planned sample size; these
sites are to be confirmed. All regulatory and ethical ap-
provals will be in place before the trial starts at each site.
Eligibility criteria
The CRASH-3 IBMS will be conducted in a cohort of
approximately 1000 adult trauma patients enrolled in
the CRASH-3 trial. Patients who have a Glasgow Coma
Scale score of 12 or less or intracranial bleeding on a CT
scan performed before randomisation into the CRASH-3
trial (i.e., a pre-randomisation CT scan), and fulfil the
inclusion criteria for the CRASH-3 trial, are eligible for
inclusion in the CRASH-3 IBMS [36].
Randomisation into the CRASH-3 trial
TBI patients eligible for inclusion into the CRASH-3
trial are randomly allocated to receive tranexamic acid
or matching placebo (0.9% sodium chloride) and the trial
treatment is started as soon as possible. Patients are ran-
domised by selecting the lowest available numbered pack
from a block of eight treatment packs. Randomisation
codes are generated with a computer random number
generator. There is no need to withhold any clinically in-
dicated treatment in the CRASH-3 trial. Tranexamic
acid or placebo is provided as an additional treatment to
the usual management of TBI. The loading dose of the
trial treatment is administered by intravenous injection
immediately after randomisation (within minutes). The
maintenance dose (by intravenous infusion) should start
as soon as the loading dose is completed.
Adverse events in the CRASH-3 trial
Any untoward medical occurrence affecting a trial patient
up to 28 days after randomisation will be reported in line
with the CRASH-3 trial protocol. If the patient develops
Fig. 1 Schedule of enrolment, intervention and assessment in the CRASH-3 trial and CRASH-3 IBMS
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an adverse event during the treatment phase, the trial drug
should be stopped. In this situation, the patient should be
treated in line with local procedures and then followed up.
The independent Data Monitoring Committee may rec-
ommend for the early termination of the trial, and the
final decision lies with the Trial Steering Committee.
Unblinding before the end of the CRASH-3 trial
If there are contraindications to tranexamic acid following
randomisation, the trial treatment should be stopped and
all standard clinical care provided. Unblinding is only ne-
cessary if the clinician believes that clinical management
depends importantly upon knowledge of whether the pa-
tient received tranexamic acid or placebo. In this case, a
24 hour telephone service is available to confirm whether
the patient received tranexamic acid or placebo.
Outcomes and outcome measurement
Primary outcome
The total volume of intracranial bleeding after randomisa-
tion, adjusting for total volume of intracranial bleeding at
baseline if baseline volume is available.
Secondary outcomes
(1)Frequency of progressive haemorrhage – number of
patients with a post-randomisation CT scan with
total haemorrhage volume of more than 25% of the
volume on the pre-randomisation scan;
(2)Frequency of new haemorrhage – number of patients
with haemorrhage on the post-randomisation CT scan
when there was not one on the pre-randomisation scan;
(3)New focal ischaemic lesions – ischaemic lesions
which appear on a post-randomisation scan but not
on the pre-randomisation scan;
(4)Total volume of intracranial bleeding after
randomisation in patients who undergo surgical
evacuation of haemorrhage, adjusting for volume of
baseline bleeding.
All outcomes will be compared across treatment groups.
Outcome measurement: estimating haemorrhage volume
Patients often undergo one brain CT scan as part of routine
medical care prior to randomisation into the CRASH-3
Fig. 2 CRASH-3 trial inclusion criteria (blue boxes show additional procedure for the CRASH-3 Intracranial Bleeding Mechanistic Sub-Study)
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trial. The majority of patients are scanned again after
randomisation into the CRASH-3 trial. In the CRASH-
3 IBMS, we will measure the volume of intracranial
haemorrhage on pre- and post-randomisation CT scans.
A simple validated scale for measuring intracranial
haemorrhage volume shows good agreement with the
gold standard of computer-assisted volumetric analysis,
which requires demarcation of the haemorrhage bor-
ders [38–49].
The ABC/2 method is a quick and easy technique used
to estimate the volume of intracranial haemorrhage [50].
This method assumes haematoma volume is approximately
equal to an ellipsoid shape (i.e., three dimensional oval
shape). For ease of assessment, the formula for calculating
the volume of an ellipsoid (4/3 × π × (A/2) × (B/2) × (C/2))
can be simplified to ABC/2 if we assume π is equal to 3.
This method selects a representative slice near the centre
of the haematoma on which the bleed is most visible. On
this slice, two measurements are taken: (A) the maximal
diameter; (B) width perpendicular to A. For the measure-
ment of depth, the maximal number of slices on which the
haematoma is visible is multiplied by slice thickness (C).
These three measurements are multiplied and the sum di-
vided by two (ABC/2) to provide the volume measurement
in cm3.
Whilst some researchers have found that the ABC/2
method overestimates lesion volume compared to
computer-assisted methods [39, 44, 45, 47, 51–55],
others claim the opposite [41, 56]. Haemorrhagic lesions
that have a regular shape are more accurately estimated
using the ABC/2 method compared to lesions with
irregular or multi-lobular shapes [43, 45–56]. Further-
more, a number of variations of the ABC/2 method
adjust for the depth of a lesion. Whilst some have
found that adjusting for depth significantly underesti-
mates volumes because smaller slice volumes are eli-
minated [57], others found that adjusting for depth is
favourable [48].
Although the ABC/2 method is a less specific measure
of haemorrhage volume and overestimation due to false
positives would dilute the effect of the treatment to-
wards the null, its low sensitivity and underestimation
due to false negatives would not impact the effect of the
treatment on haemorrhage. Furthermore, the more ac-
curate method of estimating haemorrhage would have
been more expensive and therefore administered in a
smaller number of patients given the limited budget of a
clinical trial. Although a more accurate method in a
small trial would result in less measurement error, a less
accurate method in a larger trial would result in less ran-
dom error. We believe that the ABC/2 method is suffi-
ciently accurate and therefore chose to use this method
in a larger trial. Furthermore, the assessor rating the
scans will be blind to treatment allocation and thus the
bias from measurement error should be balanced be-
tween treatment groups.
Total haemorrhage volume
The total haemorrhage volume on each scan will be cal-
culated by totalling the volumes of intra-parenchymal,
intra-ventricular, epidural and subdural haemorrhage.
Estimating intra-parenchymal, intra-ventricular and epidural
haemorrhage volume using ABC/2
Volume estimation of intracranial haemorrhage is aided
by the characterisation of haematomas. The final shape
of a haematoma is influenced by its location. Intra-axial
(or intra-cerebral) haematomas include intra-parenchymal
haematomas, which occur in the brain tissue, and intra-
ventricular haematomas, which occur in the ventricles of
the brain. These haematomas tend to have regular shapes
that are clearly definable in every dimension (i.e., their
length, width and depth can be measured on a CT scan).
Extra-axial haematomas occur between the three mem-
branes that surround the brain (dura mater, arachnoid
mater and pia mater). Epidural haematomas are a type of
extra-axial haematoma and occur between the skull and
outer membrane of the central nervous system (dura
mater). They have a clear shape that can be measured in
every dimension. The ABC/2 method assumes the haem-
orrhage has an ellipsoid shape and has been validated in
intra-parenchymal [38], intra-ventricular [46] and epidural
haematomas [47, 48]. We will estimate the volume of
intra-parenchymal, intra-ventricular and epidural/extra-
dural haemorrhage using the ABC/2 method.
Estimating subdural haemorrhage volume using
maximum width
Subdural haematomas are another type of extra-axial
haemorrhage and occur between the dura mater and the
middle membrane of the central nervous system (arach-
noid mater). Subdural haematomas are crescent shaped
as they follow the pattern of the brain’s convexity. The
exact limits of a subdural haematoma are not clearly de-
finable in any dimension. This type of haemorrhage can
theoretically occupy the entire subdural space. Given
that the ABC/2 method assumes the haemorrhage has
an ellipsoid shape, it would not provide an accurate vol-
ume estimation of subdural haemorrhage. Indeed, there
have been reports of underestimation in subdural haem-
orrhage volume when using an adapted version of the
ABC/2 method compared with computer-assisted volu-
metric analysis [41, 56].
Some researchers and clinicians propose that it is
more appropriate to estimate subdural haemorrhage vol-
ume using a formula which takes the difference between
two spheres (representing the entire subdural space),
divides by two (as subdural haemorrhage is usually
Mahmood et al. Trials  (2017) 18:330 Page 6 of 13
unilateral) and divide by two again (as subdural haem-
orrhage tends to be thicker at the centre and thinner at
the sides). This method has been tested at the Neuro-
surgical Trauma Unit at the Queen Elizabeth Hospital
in Birmingham (UK) and has been shown to provide more
clinically relevant estimates of haemorrhage volume than
the ABC/2 method [58]. Although this method overesti-
mates subdural volume, it is less than the error provided
by the ABC/2 method. The key measurement in determin-
ing the clinical significance of a subdural haemorrhage is
its thickness (i.e., the B measurement when using the
ABC/2 method) [59]. In the CRASH-3 IBMS, we will
measure the maximum width of a subdural bleed, and
compute its volume using the aforementioned formula.
Measurement of subarachnoid haemorrhage
Subarachnoid bleeds are another type of extra-axial
haemorrhage and occur in the area between the arachnoid
membrane and the innermost membrane surrounding the
brain (pia mater). The shape of the subarachnoid space re-
sembles a spider’s web and therefore haemorrhage in the
subarachnoid space cannot be clearly measured in any di-
mension. Although there are a number of CT grading
scales that include the characterisation of subarachnoid
haemorrhage [60, 61], they are criticised for being subject-
ive and not comprehensive enough to serve as a primary
grading scale for this type of haemorrhage [62]. For ex-
ample, the Fisher scale and its modified version do not
consider subarachnoid haemorrhage in isolation but in
combination with intraventricular haemorrhage [63].
In the CRASH-3 IBMS, the size of a subarachnoid
haemorrhage will be characterised as small, medium or
large. Each bleed will then be described as focal (local-
ised to a specific location), multiple (not localised but
not widespread) or diffuse (widespread). This method is
also subjective and may have low sensitivity and specifi-
city, therefore misclassification would bias the effect of
the treatment towards the null value. We hope that, by
using this method in a large trial, the bias from measure-
ment error would be offset by a reduction in random
error.
Petechial haemorrhage
Petechial haemorrhage manifests as a very small dot on
a CT scan. CT scans and accompanying radiology re-
ports will be examined to indicate whether petechial
haemorrhage is present.
Outcome measurement: focal ischaemic lesions
Ischaemic stroke is due to the compromise of blood
and oxygen flow through either large or small arteries
supplying the brain parenchyma. Thrombotic occlusion
of intracranial vessels produce wedge-shaped cortical
infarctions.
Cerebral ischaemia would reliably manifest on a CT
scan performed at least 48 hours after randomisation
[62]. However, given that clinical scans are performed
for diagnostic purposes, it is not possible to carry out
scans at set time points post-randomisation. Brain im-
aging techniques, including MRI diffusion weighted im-
aging, have higher sensitivity and specificity compared
to CT in the early diagnosis of ischaemic infarction,
and are often clinically warranted when there is a sus-
pected stroke. Therefore, the assessor will examine all
available brain scans performed within 28 days of ran-
domisation and the accompanying radiology reports for
evidence of focal ischaemic lesions and record the time
from randomisation to detection.
Furthermore, given that CT imaging is the first and
most common neuroimaging examination performed for
emergency assessment of suspected acute haemorrhage
and stroke around the world [64, 65], the majority of
scans included in the CRASH-3 IBMS will be CT scans.
Therefore, it is important to clarify how we will capture
this endpoint when only CT scans are available. Cerebral
infarction manifests as wedge-shaped low attenuation on
a CT scan. Given that oedema also manifests as low at-
tenuation on CT, the radiology reports that accompany
CT scans should indicate whether the low attenuation is
representative of oedema or infarction. Brain imaging re-
ports often refer to cerebral infarction by the affected
vascular territory (e.g., anterior cerebral artery, middle
cerebral artery, posterior cerebral artery, lacunar, cere-
bellar, brainstem). The assessor will examine all available
brain imaging to assess whether oedema or infarction
can be excluded given the appearance of earlier scans. For
example, some patients have oedematous haemorrhagic
lesions, which on CT manifests as high density haemor-
rhage surrounded by low density oedema. In later scans
the haemorrhage may resolve but the oedema may remain.
If only considered alone, the later CT scan may have
the appearance of infarction but could be representa-
tive of residual oedema. We will attempt to minimise
such errors by comparing the appearance of cerebral
infarction/oedema between consecutive scans, and con-
sider the accompanying scan reports for radiological
opinion. If the available scans and accompanying reports
are unable to confirm the presence of an ischaemic lesion,
we would seek further radiological and clinical opinion.
Outcome measurement: mass effect and other CT
endpoints
Space-occupying intracranial lesions can displace brain
tissue. The shift of midline structures past the centre line
of the brain will be measured in millimetres. We will also
record whether mass effect has caused ventricular and
sulcal effacement.
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All scans will be rated according to the Marshall clas-
sification – the most extensively used CT classification
scale in TBI [66]. Three main characteristics define the
Marshall classification, namely presence of mass lesion,
degree of compression of perimesencephalic cisterns and
degree of midline shift.
Sample size
Assuming the average baseline intracranial bleeding volume
is 20 mL and assuming the same average increase (8 mL),
standard deviation (28 mL) and correlation (rho = 0.6) be-
tween baseline and follow-up bleeding volumes as in the
control group of the CRASH-2 Intracranial Bleeding Sub-
study [34], a study with at least 1000 participants will have
80% power (at alpha = 0.05) to detect a 15% lower bleeding
volume in the tranexamic acid group at follow-up (i.e.,
24 mL tranexamic acid vs. 28 mL placebo). In the main
CRASH-3 trial, we hypothesise that tranexamic acid
will reduce intracranial bleeding by approximately 15%.
The sample size estimates have been reviewed and ap-
proved by statisticians at the London School of Hygiene
and Tropical Medicine.
Data collection, management and analysis
Procedures for data collection
The CRASH-3 trial database will be used to prepare a
list of all patients with a Glasgow Coma Scale score of
12 or less or with a pre-randomisation CT scan at par-
ticipating sub-study hospitals. The list will include
unique randomisation (box and pack) numbers, date and
time of randomisation, and time between injury and ran-
domisation into the CRASH-3 trial. The randomisation
numbers will be used at the participating site to identify
the patient using their hospital number. The latter will
be used at the participating hospital to identify the pa-
tient. The outcome assessor (research fellow with train-
ing in brain imaging assessment) will hold a letter of
access at the participating hospital and use the patient
hospital number to retrieve pre- and post-randomisation
scans from the hospital imaging system. The outcome
assessor will complete the outcome forms at each site
using the relevant scans and accompanying radiology
reports. All the data are collected by the same outcome
assessor who is blind to treatment allocation.
If the patient does not have a pre-randomisation scan,
only the post-randomisation scan form is completed. If
the patient does not have a post-randomisation scan,
only the pre-randomisation scan form is completed. We
record whether pre- and/or post-randomisation scans
are available such that we can examine missing data by
trial arm.
In most cases, the post-randomisation scan is the first
scan performed after randomisation, which is normally
within 72 hours of randomisation. Furthermore, due to
ongoing clinical management, some patients are scanned
within minutes of randomisation. Tranexamic acid would
not have had sufficient opportunity to effect haemorrhage
or infarction in such a way that would manifest on a scan
this soon after randomisation. Therefore, for patients
scanned within minutes of randomisation, we also meas-
ure all the outcomes of interest on the next available post-
randomisation scan, which is normally closer to 72 hours
of randomisation. All available brain imaging is examined
for evidence of focal ischaemic lesions.
The time stamped on the scans will be used to calculate
the following time intervals: (1) the time between injury
and the pre-randomisation CT scan and (2) the time
between randomisation into the trial and the post-
randomisation scan. If a patient has undergone neuro-
surgery following their injury, information on the date
and time of neurosurgery will be collected using pro-
spective reports including patient anaesthetic charts.
The outcome data is collected for all patients included
in the CRASH-3 IBMS (unless consent was withdrawn)
irrespective of whether the trial treatment was received
(i.e., on an intention-to-treat basis). The outcome data
is directly uploaded into an electronic database accessed
at each sub-study site.
Data management plan
A data management plan will be prepared in advance
of data collection (Additional file 2). This will detail all
aspects of data collection and recording to ensure compli-
ance with International Conference on Harmonisation
Good Clinical Practice guidelines (ICH-GCP) [67], United
Kingdom Clinical Trials Regulations and the Data Pro-
tection Act [68]. Data will be recorded in a database de-
veloped in line with relevant regulatory requirements,
including ICH-GCP guidelines.
Statistical analysis
Primary outcome A linear regression model will exam-
ine the primary outcome; whether receipt of the trial
treatment can predict total haemorrhage volume follow-
ing randomisation. Mean haemorrhage volume will be
compared between trial arms, adjusting for baseline
haemorrhage volume. Adjusting for baseline haemorrhage
volume is important as it is a strong predictor of haema-
toma increase [17, 69, 70], meaning that the baseline ad-
justment can increase the power of the comparison by
reducing the impact of between-patient variability. We
will conduct subgroup analysis to examine whether the ef-
fect of tranexamic acid on intracranial haemorrhage is
modified by time to treatment. A subgroup analysis by
time is important as previous evidence suggests that the
effect of tranexamic acid is strongly dependent on how
quickly after injury it is received (CRASH-2).
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Secondary outcomes We will express the effect of
tranexamic acid on the occurrence of dichotomous CT
endpoints, including progressive haemorrhage or new
haemorrhage, using relative risks and 95% CIs esti-
mated using generalised linear models.
We will express the effect of tranexamic acid on new
focal cerebral ischaemic lesions measured at several
post-randomisation time-points using relative risks and
95% CIs estimated using generalised linear mixed models
to account for the fact that this outcome could be mea-
sured at several time-points following randomisation.
Missing data In line with the Consolidated Standards of
Reporting Trials [71], we will report the number of pa-
tients without pre- and post-randomisation scans by
treatment arm. If the outcome of interest (haemorrhage
expansion) is associated with the reason the data are
missing (patients with haemorrhage expansion may be
more likely to die before the second scan), imbalance in
missing data by treatment group can cause bias. If we
suspect that data are missing not at random [72], we will
conduct sensitivity analysis to explore the implications.
Between-centre effects There is no evidence for the hy-
pothesis that between-centre differences in unfavourable
outcome affect the chance of demonstrating a treatment
effect in randomised trials of TBI [73]. This study esti-
mated the between-centre differences beyond the random
variation that may result from some centres that only treat
a small number of patients. Given this evidence and that
we have no biological or mechanistic explanation to ex-
pect any variation in a treatment effect between centres,
we do not anticipate to find centre effects in the CRASH-
3 IBMS. Furthermore, the majority of hospitals included
in the CRASH-3 IBMS are in western countries. The
homogeneity in patient characteristics and care facilities is
further reason not to expect a between-centre difference
in treatment effect. However, for the purpose of transpar-
ency we will report the interaction between centre and
treatment effect using a logistic regression model with
interaction between centre and treatment.
Inter-rater reliability The inter-rater reliability of
haemorrhage occurrence will be assessed using relevant
Entry Form data from the CRASH-3 trial to examine
consistency among ratings provided by the research fel-
low and clinical staff.
Interim and final analyses There are no interim ana-
lyses planned for the CRASH-3 IBMS. The final analysis
for the CRASH-3 IBMS will be undertaken following
completion of the main CRASH-3 trial. A complete stat-
istical analysis plan will be published separately prior to
completion of the CRASH-3 trial.
Monitoring
All data for the CRASH-3 trial will be subject to statis-
tical monitoring and approximately 10% of data will be
subject to on-site monitoring. Consent forms will be
monitored centrally by the Trial Coordinating Centre
(where permission is given to do so). Investigators/insti-
tutions are required to provide direct access to source
data/documents for trial-related monitoring, audits, ethics
committee review, and regulatory inspection. All trial-
related and source documents must be kept for at least
5 years after the end of the trial. As all the CRASH-3
IBMS data will be collected directly from source data,
additional monitoring will not be carried out for this data.
Potential risks
The effective radiation dose from a CT scan is about
2 mSv, which is approximately the amount received from
background radiation in 8 months. Because CRASH-3
IBMS will mainly use data from CT scans undertaken as
part of routine patient care, patients will not be exposed
to extra radiation. There is no additional burden or risk
to the patient as a result of CRASH-3 IBMS. It is stand-
ard care for all patients with TBI and associated clinical
signs to have a CT scan. Follow-up CT scans are often
conducted for diagnostic purposes around 24 to 72 hours
after the initial scan. Steps taken to minimise the risks
associated with handling personal data will be detailed
in the Confidentiality section.
Confidentiality and dissemination
Confidentiality
Only staff with authorised access to the scans, either as
clinicians or research contract holders, will be able to re-
trieve and review them. Completed scan data forms will
be uploaded onto a secure database. The scan data forms
will contain no patient identifiable data (Additional file 3).
Scans include the date and time of the scan and this infor-
mation could potentially be used by anyone with access to
the hospital radiology system to identify the patient. For
this reason, scan data forms will only include the random-
isation number, the time interval between the injury and
the scan (pre-randomisation scan form), and the time inter-
val between randomisation and the scan (post-randomisa-
tion scan form). As no personal data will be collected, the
anonymity of each patient will be protected.
Publication
The results from this trial will be published in peer-
reviewed medical journals. Dissemination of results to
patients will take place via the media, trial website
(crash3.lshtm.ac.uk) and relevant patient organisations.
All participating sites will be credited in key
publications.
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Discussion
Potential benefit of CRASH-3 IBMS: furthers knowledge
about mechanism of action of tranexamic acid in TBI
The CRASH-3 IBMS is a nested randomised trial that will
reliably examine the effect of tranexamic acid on intracra-
nial haemorrhage and cerebral ischaemia. We hope that
this trial will provide information about the mechanism of
action of tranexamic acid in isolated TBI. An understand-
ing of the mechanism of action of tranexamic acid and
insight into factors that might affect this mechanism, is
critical in the appropriate generalisation of trial results
[74]. If patients who receive tranexamic acid have less
intracranial bleeding on their CT scans compared to those
who receive placebo, this information, along with the re-
sults of the main CRASH-3 trial, could inform the admin-
istration of tranexamic acid in TBI. If TBI patients who
receive tranexamic acid soon after injury have less haem-
orrhage expansion compared to those who receive tranex-
amic later, then time between injury and treatment is a
factor relevant to the mechanism of action which, with the
results of the main CRASH-3 trial, should be considered
when making treatment decisions. Furthermore, if we find
evidence of cerebral ischaemia in patients who receive
tranexamic acid and the effect varies by time to treatment,
this information can be used to prevent adverse outcomes
and ensure those receiving tranexamic acid are those most
likely to benefit from it. Therefore, the knowledge gained
from the nested CRASH-3 IBMS will add to the evidence
base and could benefit the clinical management of patients
with head injuries.
Furthermore, the patients included in the CRASH-3
IBMS are likely to have more severe head injuries com-
pared to patients in the CRASH-3 trial but not included in
the CRASH-3 IBMS. The patients in the sub-study are not
a random sample of patients in the CRASH-3 trial, nor
will they be comparable. It is not necessary for the sub-
study population to be representative of the CRASH-3
trial population because knowledge about a causal mech-
anism facilitates generalisation and not representativeness
of the trial patients [75]. If the sub-study used a random
sample of patients from the CRASH-3 trial, the results
would not necessarily apply to either more or less severe
patients, but only to a hypothetical patient of average in-
jury severity. Representativeness of trial patients does not
help us to generalise our findings to other TBI patients.
Knowledge about whether tranexamic acid reduces intra-
cranial bleeding or increases cerebral ischaemia will in-
form the administration of tranexamic acid in TBI and
allow us to appropriately generalise the trial results.
Potential dangers of CRASH-3 IBMS: power and alternative
mechanisms leading to death in TBI
The CRASH-3 trial and CRASH-3 IBMS are based on the
premise that intracranial haemorrhage is the mechanism
that leads to death in patients with TBI. We hypothesise
that tranexamic acid will reduce intracranial haemorrhage,
which will in turn reduce the risk of death and disability.
We assume that, by inhibiting fibrinolysis, tranexamic acid
increases blood viscosity, reduces blood flow and slows
the rate of haemorrhage (Poiseuille’s Law [76]). However,
it is possible that tranexamic acid does reduce intracranial
haemorrhage but the CRASH-3 IBMS might not have suf-
ficient power to detect such an effect. Our sample size cal-
culation is based on a specific difference in haemorrhage
volume between treatment groups. If receiving tranexamic
acid results in a smaller reduction in haemorrhage volume
than we have assumed, the CRASH-3 IBMS might not
detect it and we may falsely conclude that tranexamic
acid does not reduce intracranial haemorrhage. This is
a limitation of conducting this nested sub-study in a
smaller population of the main trial population. There is a
trade-off between a larger sample, which would allow us
to detect a smaller treatment effect and time, and re-
sources; therefore, we have estimated a realistic sample
size based on the best available evidence in this area.
Furthermore, if tranexamic acid reduces intracranial
haemorrhage in TBI patients and this is detected by the
CRASH-3 IBMS, it is still possible that clinical outcomes
may not improve. This could be because intracranial
haemorrhage is not the mechanism that leads to death
in TBI patients. It is also possible that the potential
benefit of tranexamic acid in reducing intracranial
haemorrhage may be offset by the increased risk of cere-
bral ischaemia [29, 30], particularly when administered
several hours after injury when there is an increased risk
of thrombotic disseminated intravascular coagulation
[25]. The CRASH-3 IBMS will provide information on
both endpoints and could aid the interpretation of re-
sults from the CRASH-3 trial.
Trial status
The first patient was enrolled in the CRASH-3 trial on
20 July 2012. Recruitment is currently ongoing. It is an-
ticipated that recruitment for the CRASH-3 trial will be
complete by 31 December 2017. Data collection for the
CRASH-3 IBMS started in February 2016. All data for
the CRASH-3 IBMS will be collected prior to completion
of the CRASH-3 trial.
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